David Geier, Mail Order Pharmacist

Every few years, a name pops up in the world of vaccines and autism that makes scientists,
regulators, and parents collectively raise an eyebrow. Lately, one of those names has been
David Geier – long-time vaccine skeptic, son of a de-licensed physician,
and, more recently, operator of a mail order pharmaceutical business scrutinized by the FDA.
Science-Based Medicine (SBM) has chronicled his story in detail, and it reads like a cautionary
tale about what happens when weak evidence, strong ideology, and shaky quality control collide.

In this article, we’ll unpack who David Geier is, why “mail order pharmacist” is not as reassuring
a title as it sounds in his case, and what his history tells us about the importance of
science-based medicine and rigorous pharmacy regulation.
Along the way, we’ll contrast his story with what well-run mail order pharmacies actually do for
patients and offer some practical tips to help you spot red flags before your prescriptions
ever hit your doorstep.

Who Is David Geier?

First, an important clarification: despite sometimes being treated as a “doctor” in media
narratives, David Geier is not a physician. He holds a bachelor’s degree
in biology, not a medical degree, and has never been licensed to practice medicine.

Geier came to prominence not through mainstream medical research but as part of a
vaccine–autism activist duo with his father, Dr. Mark Geier. Together,
they promoted controversial hypotheses claiming that vaccines, particularly those containing
thimerosal, caused autism. Their “research” has been repeatedly and strongly criticized by
scientists, public health agencies, and courts for poor methods and misuse of data.

Despite this track record, reporting in 2025 revealed that Geier was brought into federal
work examining possible links between vaccines and autism, raising alarm among physicians,
health policy experts, and vaccine advocates who pointed to his long history of
vaccine skepticism and disciplinary issues.

The Geier Family and the Vaccine–Autism Myth

To understand why the Science-Based Medicine article focuses so heavily on Geier’s mail order
pharmaceutical activities, you have to know the backstory. For years, Mark and David Geier
promoted a highly speculative “Lupron protocol” for autistic children. The idea combined:

• The debunked claim that autism is essentially a form of mercury poisoning from vaccines.
• The theory that testosterone binds mercury and makes it harder to remove.
• A proposed fix: suppress testosterone with drugs like Lupron and pair it with chelation
  therapies intended to remove heavy metals from the body.

This protocol was not supported by robust clinical trials, not endorsed by major medical
organizations, and was widely condemned as unsafe and non–evidence-based.
Investigations by the Maryland Board of Physicians found that Mark Geier misdiagnosed patients,
failed to conduct adequate exams, used risky treatments without solid evidence, and misrepresented
his credentials. His medical license was suspended and later permanently revoked in every state
where he had been licensed.

David Geier was not just answering phones in this operation. Board findings showed he evaluated
at least one child, interpreted questionnaires, chose and ordered lab tests, and otherwise acted
as a clinician without a medical license. The Board concluded that he was
practicing medicine illegally and described his testimony as misleading and not credible,
ultimately fining him and issuing a cease-and-desist order.

From Autism “Treatments” to Mail Order Pharmacy

After the Maryland proceedings and the collapse of their autism clinic model, the Geier family
relocated to Florida. Around this time, Mark Geier faced additional action from Florida
regulators for engaging in what the Board described as the unlicensed practice of pharmacy,
compounding and dispensing hormonal drugs to dozens of patients without proper oversight.

Meanwhile, in 2011, David Geier created a company called
DAP Pharmaceuticals, LLC, registered in Florida. Corporate filings identified
him as the manager of the firm, yet public records from the Florida Board of Pharmacy indicate
he does not hold a pharmacy license in that state.

DAP Pharmaceuticals was classified by the FDA as an
API repackager – a business that repackages active pharmaceutical ingredients
for further use. That’s a high-responsibility job: what comes out of such a facility can end up
in capsules, vials, or compounded products that patients take every day. When you handle active
drug ingredients, regulators expect meticulous documentation, quality assurance, and compliance
with good manufacturing practice (cGMP).

Unfortunately, when FDA inspectors visited DAP’s facility in 2019, what they found set off
more alarms than a hospital code blue.

What a Good Mail Order Pharmacy Looks Like

Before we dig into the FDA’s findings, it’s worth clarifying an important point:
mail order pharmacy itself is not the villain here. In fact, research in large
U.S. health systems has shown that patients who use reputable mail order pharmacies often have
better medication adherence and improved control of chronic conditions like
high blood pressure and high cholesterol compared with traditional retail pharmacy users.

Well-run mail order operations typically have:

• Licensed pharmacists overseeing dispensing and patient counseling.
• Robust computerized systems to prevent drug interactions and dosing errors.
• Strict temperature and storage controls, especially for sensitive drugs.
• Documented quality checks and batch records for every medication shipped.
• Accreditation from independent bodies and a trail of regulatory inspections.

When those pieces are in place, mail order pharmacy can be a safe, convenient option that saves
patients time and sometimes money. But if you strip away the licensing, documentation, and
oversight, you don’t get innovation – you get risk.

Inside DAP Pharmaceuticals: What FDA Found

In September 2019, FDA investigators inspected DAP Pharmaceuticals’ facility in Lake Park,
Florida. Their report, summarized in the SBM article and public documents, makes for sobering
reading. The inspection found multiple categories of noncompliance with basic drug-handling
standards, including:​

• No stability data to justify how long repackaged active ingredients could
  safely be used or how they should be stored.
• No identity testing of incoming active pharmaceutical ingredients, and no
  meaningful qualification of suppliers.
• No proper batch records or master packaging and labeling documents to
  accurately track what was repackaged and how.
• Inadequate written procedures describing how packaging and labeling
  materials should be received, checked, and released.
• No consistent Certificates of Analysis (COAs) being sent to customers with
  shipments, depriving them of essential information about the materials’ quality.
• No independent quality unit – the same personnel were doing production and
  quality control, which is a classic compliance no-no.
• Insufficient staff training in cGMP and in the specific operations they were
  performing.
• Unvalidated cleaning and sanitization procedures, raising the risk of
  contamination or residual chemicals on equipment.

The FDA classified the inspection as “Official Action Indicated” – its highest level of concern,
signaling serious regulatory violations that may require enforcement action.

When you connect this inspection to Geier’s history in the vaccine–autism world, a pattern
emerges: insufficient respect for regulatory standards, inadequate documentation, and a willingness
to operate at the edge (or outside) of professional roles and qualifications.

Why This Matters for Evidence-Based Medicine

You might wonder: why does a somewhat obscure mail order API repackager deserve this much
attention? The answer lies in how Geier has also been positioned in high-stakes conversations
about vaccines, autism, and federal policy.

Reports in 2025 indicated that Geier was being given access to sensitive vaccine safety data
held by the federal government and was linked to a new federal study examining alleged autism
risks from vaccines, under the leadership of HHS Secretary Robert F. Kennedy Jr.

That combination – a history of unlicensed practice, involvement in a discredited autism
“treatment,” and serious FDA quality-control findings – raises legitimate questions about
judgment, conflict of interest, and scientific rigor. Science-based medicine depends not just
on data, but on:

• Transparent methods that other researchers can examine and replicate.
• Appropriate expertise in the design and conduct of studies.
• Independence from ideological or financial pressures that might distort
  interpretations.
• Respect for regulatory norms that protect patients and data integrity.

If someone’s track record shows repeated clashes with medical boards, courts, and the FDA
over those very issues, skepticism is not cynicism – it’s common sense.

How Patients and Parents Can Protect Themselves

The Geier story is dramatic, but the practical lessons for everyday people are very grounded.
You don’t need to memorize every FDA regulation; you just need to know how to spot warning
signs and how to lean on trustworthy systems.

1. Check licenses and credentials

If someone is diagnosing, prescribing, or recommending aggressive medical treatments for your
child, you should be able to verify their professional license with a state medical or pharmacy
board in a matter of minutes. In the Geier case, board orders and court decisions were publicly
available and clearly described the problems.

2. Be skeptical of “miracle cures” for autism

Major medical organizations do not recommend hormone suppression, chelation, or unapproved
drug cocktails as standard treatments for autism. Autism is a complex neurodevelopmental condition,
not a simple toxin problem that can be flushed out with a pill or a shot. If a clinic promises to
“reverse” autism with expensive interventions that sound nothing like what mainstream pediatric
or neurology groups endorse, that’s a red flag, not a breakthrough.

3. Choose mail order pharmacies that embrace oversight

If you use mail order pharmacy services, look for:

• Clear information about who owns and operates the pharmacy.
• State licenses and, ideally, third-party accreditation.
• Easy access to a licensed pharmacist for questions.
• A willingness to talk about safety, temperature control, and returns.

“Shadow” operations that sit in regulatory gray zones, especially if run by people with
disciplinary histories, deserve extra scrutiny.

4. Use credible sources for vaccine information

Vaccine safety is one of the most heavily studied topics in modern medicine. High-quality
evidence consistently shows that vaccines do not cause autism, while they
do prevent serious infectious diseases. When evaluating claims, look to sources like the CDC,
academic medical centers, and peer-reviewed journals rather than activists with a long trail
of failed lawsuits and disciplinary actions.

Experiences and Reflections Around the Geier Case (Extended)

It’s one thing to read regulatory documents and court opinions; it’s another to imagine what
these situations look like from the standpoint of the people affected. While we can’t and
shouldn’t invent specific patient stories about real individuals, we can look at patterns and
typical experiences that arise in similar scenarios.

Picture parents of a newly diagnosed autistic child in the early 2000s. They’re exhausted,
anxious, and trying desperately to do “everything possible” to help their child. They search
online and find glowing testimonials for a protocol that promises not just improvement, but
recovery. The language is scientific-sounding – hormones, receptors, chelators, detoxification –
and it’s often presented by people who appear to be “experts” in the field. In that environment,
it’s easy to understand how families could be drawn into expensive, unproven treatments.

Many clinicians have described what it’s like to meet these families later on: the child has
endured repeated blood tests, painful injections, and side effects, yet the promised transformation
never came. Parents may feel embarrassed, angry, or betrayed – or they may double down, unable
to accept that the time and money they invested might have been misdirected. Clinicians then have
to walk a tightrope: acknowledging those feelings while gently guiding families back toward
evidence-based interventions like behavioral therapies, speech and occupational therapy, and
supportive educational services.

Now add in the mail order pharmacy element. For many families, medications simply arrive at their
doorstep in a steady stream. When the operation behind those shipments is well-regulated,
that’s a convenience. When it isn’t, patients might never see the warning signs:

• Labels that don’t quite match what their doctor described.
• Drugs sourced from manufacturers they’ve never heard of.
• Lack of clear instructions or counseling about side effects.
• No obvious way to reach a responsible pharmacist with concerns.

Health professionals reading the Science-Based Medicine account of DAP Pharmaceuticals and
Geier’s history have reacted with a mix of frustration and grim familiarity. Many have their
own stories of confronting poorly supported “protocols” in practice – whether it’s extreme
diets, high-cost supplements, or aggressive hormone regimens pushed as cures for autism and
other complex conditions. They see the same themes repeat: charismatic promoters, selective
citation of weak studies, and a disregard for the ordinary guardrails of medical practice
like peer review, ethics committees, and licensing boards.

On the regulatory side, inspectors and board members often describe how labor-intensive it is
to pursue these cases. It can take years of investigations, hearings, and appeals before a license
is revoked or a cease-and-desist order is enforced. By then, many families have already cycled
through the clinic or pharmacy in question. The Geier saga is a vivid example of how determined
individuals can keep shifting roles and business entities – from clinic to consulting, from
prescriber’s office to API repackager – while regulators try to keep up.

For scientists and evidence-based medicine advocates, the most unsettling aspect is when such
individuals are later positioned as neutral investigators in high-stakes policy debates. When a
person with a long history of contentious, low-quality work on vaccines and autism is given
privileged access to federal databases and asked to lead or heavily influence major studies,
it doesn’t just risk bad science; it erodes public trust in the institutions sponsoring that
work. Researchers who have spent decades following rigorous methods understandably worry that
their field will be judged by the most controversial actors rather than by the consensus of
careful studies.

And yet, there’s a constructive takeaway here. The intense scrutiny around David Geier has
prompted renewed discussion about conflict-of-interest policies,
data access controls, and the need for transparent criteria when selecting
investigators for sensitive public health projects. It has also reminded many people – from
parents to policymakers – that credentials and regulatory histories matter. Even in a polarized
environment, there is broad agreement that patients deserve care based on solid evidence and
medications handled under rigorous quality standards.

In that sense, the “mail order pharmacist” story is something of a stress test for our systems.
When they work, regulators, journalists, and skeptical clinicians can expose problems and protect
patients before more harm is done. When they don’t, we are left relying on whistleblowers and
investigative reporters to fill the gap. Science-Based Medicine’s detailed coverage of the Geier
case is one example of how critical, evidence-focused reporting can help keep the spotlight where
it belongs: on the intersection of science, medicine, and accountability.

Conclusion: What the Geier Story Teaches Us

The story of David Geier, from unlicensed clinical work in an autism clinic to running a
troubled mail order pharmaceutical business and then resurfacing in federal vaccine–autism
debates, isn’t just about one person. It’s a window into how fringe ideas, weak evidence, and
regulatory gaps can align in ways that put patients at risk.

Science-based medicine is not perfect, but it is built on principles that – when taken seriously –
reduce harm: transparent methods, peer review, independent oversight, and licensed professionals
working within their scope. Mail order pharmacy, when operated within those guardrails, can be
a safe and useful part of modern health care. When it is not, we get inspection reports like the
one at DAP Pharmaceuticals, and articles like “David Geier, Mail Order Pharmacist” explaining
exactly why that matters.

For parents, patients, and policymakers, the practical lesson is straightforward: scrutinize
credentials, value independent oversight, and anchor your decisions in the weight of the
scientific evidence – not in the confidence of the person selling you a protocol or a pill.